The financials
Travere Therapeutics, Inc. by the numbers
Travere Therapeutics, Inc. (TVTX) reported revenue of $170M in Q2 2026 (quarter ended Jun 30, 2026), up 48% from the same quarter a year earlier. That came with a gross margin of 99% and net loss of $35M. For the full year FY2025, revenue was $491M (+110% year on year) and net income −$26M. Its largest product in Q2 2026 was FILSPARI at $141M, 83% of the disclosed total, well ahead of Tiopronin Products at 12%.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $170M | $114M | +48% |
| Gross profit | $167M | $113M | +48% |
| Operating income | $4.0M | −$13M | to a profit |
| Net income | −$35M | −$13M | n/a |
| Diluted EPS | −$0.37 | −$0.14 | n/a |
| Product | Revenue | Share |
|---|---|---|
| FILSPARI | $141M | 83% |
| Tiopronin Products | $20M | 12% |
| License | $8.2M | 4.9% |
Business Segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Q2 2026Total $169.6M (+33%)
FILSPARI grew +96% year on yearLicense -58% year on year
Segment Latestquarter on quarteryear on year
- FILSPARI$141.1M$141.1MQoQ +34%year on year +96%+34%+96%
- Tiopronin Products$20.3M$20.3MQoQ +4.8%year on year -12%+4.8%-12%
- License$8.2M$8.2MQoQ +204%year on year -58%+204%-58%